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Edited by Sandro SonninoAbstract Herein, employing a previously reported disulﬁde-
linker strategy, we have designed and synthesized a novel
cationic lipid 2 with a disulﬁde-linker and its non-disulﬁde
control analog lipid 1. The relative eﬃcacies of lipids 1 and 2 in
transfecting CHO, COS-1 and MCF-7 cells were measured
using both reporter gene and whole cell histochemical staining
assays. In stark contrast to the expectation based on the
disulﬁde-linker strategy, the control non-disulﬁde cationic lipid 1
showed phenomenally superior in vitro transfection eﬃcacies to
its essentially transfection incompetent disulﬁde counterpart lipid
2. Results in DNase I protection experiments and the electro-
phoretic gel patterns in the presence of glutathione, taken
together, are consistent with the notion that the success of the
disulﬁde-linker strategy may depend more critically on the
DNase I sensitivity of the lipoplexes than on the eﬃcient DNA
release induced by intracellular glutathione pool.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Developing clinically successful gene therapy approach for
treating myriads of inherited diseases critically depends upon
the biosafety and gene transfer eﬃcacies of the vectors used for
delivering the therapeutic genes into the body cells [1–3]. The
contemporary transfection vectors are broadly classiﬁed into
two major categories: viral and non-viral. Recombinant ret-
roviral vectors are remarkably eﬃcient in transfecting body
cells [4,5]. However, retroviral vectors are potentially capable
of: generating replication-competent virus through recombi-
nation events with the host genome; inducing inﬂammatory
and adverse immunogenic responses; producing insertional
mutagenesis through random integration into the host ge-
nome, etc. [6–9]. Additional major disadvantages associated* Corresponding author. Fax: +91-40-27160757.
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dicyclohexyl carbodiimide; NHS, N-hydroxy succinimide; DMF,
dimethyl formamide; DCM, dichloromethane; HCl, hydrochloric acid;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
X-gal, 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.06.058with the use of viral vectors include their incapability of
transfecting non-dividing cells, limited insert-size and diﬃculty
of large-scale production [4–9]. Conversely, cationic lipids,
because of their least immunogenic nature, robust manufac-
ture, ability to deliver large pieces of DNA, and ease of han-
dling and preparation techniques, are ﬁnding increasing uses
as the alternative non-viral vectors of choice in gene therapy
[10–17].
Currently believed key mechanistic steps in cationic lipid
mediated transfection pathways include formation of nano-
size lipoplexes (liposome:DNA complexes), endocytotic cellu-
lar uptake of lipoplexes, escape of DNA from endosomes into
the cell cytoplasm, traﬃcking of the endosomally released
DNA into the cell nucleus and ﬁnally transgene expression
[18–20]. Such complex transfection pathway makes rational
design of eﬃcient cationic transfection lipids an arduous task.
A number of recent structure-activity investigations [21–24],
including our own [25–30], have thrown signiﬁcant new in-
sights into the various architectural elements of cationic lipids
necessary for overcoming the above mentioned cellular barri-
ers involved in lipofection process.
Ineﬃcient release of DNA from lipoplexes into the cell cy-
toplasm is believed to be one of the major impeding factors
behind the generally poor transfection eﬃcacies of cationic
lipids. Towards this end, Tang and Hughes pioneered the use
of the disulﬁde bond as the linker functionality of cationic
transfection lipids [31,32]. The rationale behind this elegant
approach was to ensure collapsing of the lipid:DNA complex
inside the cell cytoplasm after reduction of the disulﬁde-linker
by the intracellular glutathione pool. Exploitation of such in-
tracellular disulﬁde reduction strategy has also been demon-
strated recently in the area of antisense peptide nucleic acids
(PNAs) delivery [33]. Inspired by this disulﬁde-linker strategy,
we designed and synthesized a novel cationic disulﬁde lipid 2
towards further enhancing the in vitro gene transfer property
of its novel non-disulﬁde counterpart lipid 1, an eﬃcient cat-
ionic transfection lipid recently designed in our laboratory. In
the present investigation, we report on the strikingly unex-
pected relative eﬃcacies of lipids 1 and 2 in transfecting CHO,
COS-1 and MCF-7 cells, measured using both reporter gene
and whole cell histochemical staining assays. Surprisingly, the
control non-disulﬁde cationic lipid 1 showed phenomenally
superior eﬃcacies to its disulﬁde-linker counterpart lipid 2
in transfecting all the three cells. As delineated below, results
in DNase I protection experiments and the electrophoretic
gel patterns in the presence of glutathione, taken together,
are consistent with the notion that the success of theation of European Biochemical Societies.
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DNase I sensitivity of the lipoplexes than on the eﬃcient DNA
release induced by the intracellular glutathione pool.2. Materials and methods
2.1. Materials
Dicyclohexyl carbodiimide (DCC), N-hydroxy succinimide (NHS)
and 1,2-ethylenediamine were procured from Merck, India. Column
chromatography was performed with silica gel (Acme Synthetic
Chemicals, India, 60–120 mesh). Cell culture media, fetal bovine serum
(FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), o-nitrophenyl-b-D-galactopyranoside (ONPG), b-galactosi-
dase enzyme and cholesterol were purchased from Sigma, St. Louis,
USA. NP-40, antibiotics and agarose were purchased from Hi-media,
India. LipofectAmine was purchased from Invitrogen life technologies,
USA. Unless otherwise stated all the other reagents purchased from
local commercial suppliers were of analytical grades and were used
without further puriﬁcation. 1H NMR spectra were recorded on a
Varian FT 200 MHz, AV 300 MHz or Varian Unity 400 MHz. The
FABMS analyses were performed on a Micromass AUTOSPEC-M
mass spectrometer (Manchester, UK) with OPUS V3, 1X data system.
Data were acquired by liquid secondary ion mass spectrometry
(LSIMS) using meta-nitrobenzyl alcohol as the matrix.NH-Boc
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Fig. 1. Synthesis of2.2. Syntheses
The synthetic procedures for preparing lipids 1 and 2 are depicted
schematically in Fig. 1. Detailed experimental procedures are delin-
eated below.
Synthesis of lipid 1
6-(Di-n-hexadecylamino)-6-oxohexanoic acid (I, Fig. 1): Di-n-hex-
adecyl amine (2 g; 4.3 mmol) in dichloromethane (DCM; 25 ml) was
added to dimethyl formamide (DMF; 5 ml) solution containing adipic
acid (0.69 g; 4.73 mmol), NHS (0.55 g; 4.73 mmol) and the mixture was
cooled to 0 C. DCC (0.98 g; 4.73 mmol, dissolved in 20 ml DCM) was
added dropwise to the cold solution. The reaction mixture was stirred
overnight at room temperature. The solvent mixture was removed
under vacuum and the residue was ﬁnally taken in DCM (50 ml). The
solution was washed with water (3 50 ml), dried over anhydrous so-
dium sulfate and ﬁltered. DCM was removed from the ﬁltrate on a
rotary evaporator. Silica gel column chromatographic puriﬁcation of
the resulting residue, using 60–120 mesh silica size and 1–2% methanol
in chloroform (v/v) as the eluent, aﬀorded the pure title intermediate 1.3
g (52%, Rf ¼ 0:4 in 5% methanolic chloroform, v/v).
1H NMR (200 MHz, CDCl3): d/ppm¼ 0.9 [t, 6H, CH3–(CH2)13–];
1.1–1.3 [m, 52H, –(CH2)13–]; 1.4–1.6 [m, 4H, –NCO–CH2–(CH2)2–
CH2–COOH]; 1.6–1.7 [m, 4H, –CH2–CH2–NCO–]; 2.2–2.4 [m, 4H, –
NCO–CH2–(CH2)2–CH2–COOH]; 3.1–3.3 [m, 4H, –CH2–CH2–NCO–].
Tert-butyl-(2-[6-(di-n-hexadecylamino)-6-oxohexanoyl]aminoethyl)-
carbamate (II, Fig. 1): A mixture of I (1.1 g; 1.86 mmol), N-tert-
butoxycarbonyl-1,2-ethanediamine (0.30 g; 1.86 mmol), and NHS
(0.21 g; 1.86 mmol) was taken in 20 ml dry DCM and was cooled toNH3+
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dropwise to the cold solution. The reaction mixture was stirred over-
night at room temperature. The reaction mixture was taken in DCM
(50 ml), washed with water (3 50 ml), dried over anhydrous sodium
sulfate and ﬁltered. DCM was removed from the ﬁltrate on a rotary
evaporator. Silica gel column chromatographic puriﬁcation of the re-
sulting residue, using 60–120 mesh silica size and 0.5–1% methanol in
chloroform (v/v) as the eluent, aﬀorded the pure title intermediate (1.0
g, 73.5%, Rf ¼ 0:6 in 5% methanolic chloroform, v/v).
1H NMR (200 MHz, CDCl3): d/ppm¼ 0.9 [t, 6H, CH3–(CH2)13–];
1.2–1.3 [m, 52H, –(CH2)13–]; 1.4–1.5 [m, 13H, –O–CO–C(CH3)3, –
NCO–CH2–(CH2)2–CH2–CO–NH]; 1.6–1.7 [m, 4H, –CH2–CH2–
NCO–]; 2.2–2.4 [m, 4H, –NCO–CH2–(CH2)2–CH2–CO-NH]; 3.1–3.4
[bm, 8H, –CH2–CH2–NCO–, –NH–CH2–CH2–NH–CO–]; 5.5 [bm,
1H, NHBoc]; 7.1 [bm, 1H, –CO–NH–].
2-{[6-(Di-n-hexadecylamino)-6-oxohexanoyl]amino} ethanaminium
(lipid 1, Fig. 1): Intermediate II (0.9 g, 0.35 mmol) was dissolved in 1
ml of 2 N hydrochloric acid (HCl) in dioxane and the solution was
kept under stirring at room temperature overnight. The solvent was
removed with nitrogen ﬂush and the residue was kept under vacuum
for 1 h. Silica gel column chromatography, using 60–120 mesh silica
size and 8–10% methanol in chloroform (v/v) as the eluent, aﬀorded
pure title lipid 1 (0.72 g, 86%, Rf ¼ 0:3 in 15% methanolic chloroform,
v/v).
1H NMR (200 MHz, CDCl3): d/ppm¼ 0.9 [t, 6H, CH3–(CH2)13–];
1.2–1.3 [m, 52H, –(CH2)13–]; 1.5–1.8 [dm, 8H, –NCO–CH2–(CH2)2–
CH2–CO–NH, –CH2–CH2–NCO-0]; 2.5 [m, 4H, –NCO–CH2–(CH2)2–
CH2–CO–NH]; 3.2–3.4 [m, 6H, –CH2–CH2–NCO–, –CONH–CH2–
CH2–NH
þ
3 ]; 3.6–3.7 [bm, 2H, –CONH–CH2–CH2–NH
þ
3 ]; 8.3 [bm, 1H,
–CO–NH–].
FABMS: m=z: 637 (100%).
Synthesis of lipid 2
[2-(Di-n-hexadecylamino)-2-oxoethyl]di-sulfanylacetic acid (III,
Fig. 1): Di-n-hexadecyl amine (2.0 g; 4.3 mmol) in DCM (25 ml) was
added to a solution of dithioglycolic acid (0.78 g; 4.73 mmol) and NHS
(0.54 g; 4.73 mmol) in DMF (5 ml) and the mixture was cooled to 0 C.
DCC (0.89 g; 4.73 mmol) in DCM (20 ml) was added dropwise to the
cold solution. The reaction mixture was stirred overnight at room
temperature. The solvent mixture was removed under vacuum and the
residue was ﬁnally taken in DCM (50 ml). The solution was washed
with water (3 50 ml), dried over anhydrous sodium sulfate and ﬁl-
tered. DCM was removed from the ﬁltrate on a rotary evaporator.
Silica gel column chromatographic puriﬁcation of the resulting residue,
using 60–120 mesh silica size and 1–2% methanol in chloroform (v/v)
as the eluent, aﬀorded 1.45 g (53.6%) of the pure intermediate III
(Rf ¼ 0:4 in 5% methanolic chloroform, v/v).
1H NMR (200 MHz, CDCl3): d/ppm¼ 0.9 [t, 6H, CH3–(CH2)13–];
1.2–1.4 [m, 52H, –(CH2)13–]; 1.5–1.7 [bm, 4H, –CH2–CH2–NCO–];
3.2–3.4 [m, 4H, –CH2–CH2–NCO–]; 3.6 [s, 2H, –CH2–SS]; 3.8 [s, 2H,
SS–CH2–].
Tert-butyl-[2-{[(2-N,N-di-n-hexadecylamino-2-oxoethyl)disulfanyl]-
acetyl} aminoethyl]carbamate (IV, Fig. 1): A mixture of III (1.45 g;
2.3 mmol), N-tert-butoxycarbonyl-1,2-ethanediamine (0.41 g; 2.53
mmol), and NHS (0.27 g; 2.53 mmol) was taken in 20 ml dry dichlo-
romethane and was cooled to 0 C. DCC (0.48 g; 2.53 mmol) in DCM
(20 ml) was added dropwise to the cold solution. The reaction mixture
was stirred overnight at room temperature. The reaction mixture was
taken in dichloromethane (50 ml), washed with water (3 50 ml), dried
over anhydrous sodium sulphate and ﬁltered. Dichloromethane was
removed from the ﬁltrate on a rotary evaporator. Silica gel column
chromatographic puriﬁcation of the resulting residue, using 60–120
mesh silica size and 1–2% methanol in chloroform (v/v) as the eluent,
aﬀorded 0.91 g (51.1%) of the pure intermediate IV (Rf ¼ 0:4 in 5%
methanolic chloroform, v/v).
1H NMR (200 MHz, CDCl3): d/ppm¼ 0.9 [t, 6H, CH3–(CH2)13–];
1.2–1.3 [m, 52H, –(CH2)13–]; 1.4 [s, 9H, –O–CO–C(CH3)3]; 1.5–1.7
[bm, 4H, –CH2–CH2–NCO–]; 3.21–3.37 [bm, 6H, –CH2–CH2–NCO–,
–NH–CH2–CH2–NH–]; 3.4–3.5 [m, 4H, –CH2–SS–, –NH–CH2–CH2–
NH–]; 3.55 [s, 2H, –SS–CH2–]; 5.5 [bm, 1H, NHBoc]; 8.1 [bm, 1H, –
CO–NH–].
2-[({[2-(Dihexadecylamino)-2-oxoethyl]disulfanyl}acetyl)amino]-
ethanaminium (lipid 2, Fig. 1): Compound IV (0.9 g, 1.2 mmol) was
dissolved in 1 ml of 2 N HCl in dioxan and the solution was kept under
stirring at room temperature overnight. The solvent was removed with
nitrogen ﬂush and the residue was kept under vacuum for 1 h. Silica gelcolumn chromatography using 60–120 mesh silica size and 8–10%
methanol in chloroform (v/v) as the eluent, aﬀorded 0.76 g (93%) of
pure lipid 2 (Rf ¼ 0:3 in 15% methanolic chloroform, v/v).
1H NMR (200 MHz, CDCl3): d/ppm¼ 0.9 [t, 6H, CH3–(CH2)13-];
1.2–1.3 [m, 52H, –(CH2)13–]; 1.5–1.7 [bm, 4H, –CH2–CH2–NCO–];
3.17–3.40 [bm, 6H, –CH2–CH2–NCO–, –CONH–CH2–CH2–NHþ3 ];
3.47–3.80 [m, 6H, –CH2–SS–CH2–, –CONH–CH2–CH2–NHþ3 ]; 8.1
[bm, 1H, –CO–NH–].
FABMS: m=z: 673 (70%).
2.3. Cells and cell culture
CHO (Chinese hamster ovary), COS-1 (SV 40 transformed African
green monkey kidney cells) and MCF-7 (Human breast adenocarci-
noma) cell lines were procured from the National Centre for Cell
Sciences (NCCS), Pune, India. Cells were cultured at 37 C in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) with 10% FBS, 50 lg/ml
penicillin, 50 lg/ml streptomycin and 20 lg/ml kanamycin in a hu-
midiﬁed atmosphere containing 5% CO2.
2.4. Preparation of plasmid DNA
pCMV-SPORT-b-gal plasmid was a generous gift from Dr. Nalam
Madhusudhana Rao (Centre for Cellular and Molecular Biology,
Hyderabad, India). Plasmid was ampliﬁed in DH5a strain of Esche-
richia coli, isolated by alkaline lysis procedure and ﬁnally puriﬁed by
PEG-8000 precipitation as described previously [34]. The purity of
plasmid was checked by A260/A280 ratio (around 1.85) and 1% agarose
gel electrophoresis.
2.5. Preparation of liposomes
Liposomes were prepared by the ethanol injection method. Brieﬂy,
75 ll of a 5.4 mM ethanolic solution of cationic lipids 1, 2 and Cho-
lesterol (at 2:1 mole ratio) was rapidly injected into 1 ml of HEPES
buﬀer (pH 7.4) under vortexing to give a ﬁnal cationic lipid concen-
tration of 0.4 mM. The liposomes were kept for 15 min at room
temperature before transfection.
2.6. Transfection procedure
Cells were seeded at a density of 20 000 cells/well (for CHO and
MCF-7) or 15 000 cells/well (for COS-1) in a 96-well plate usually 18–
24 h before transfection. Plasmid DNA (0.30 lg diluted to 50 ll with
plain DMEM) was complexed with varying amount of cationic lipo-
somes (diluted to 50 ll with plain DMEM) for 15–30 min. The mole
ratios (lipid:DNA) were varied from 0.5:1 to 4:1. Cells were washed
twice with PBS buﬀer (pH 7.4, 100 ll each) and the lipid:DNA com-
plex was added to the cells. After incubating for 3 h in a humidiﬁed
atmosphere containing 5% CO2 at 37 C, 100 ll of DMEM containing
20% FBS was added to the cells. The medium was changed to complete
medium containing 10% FBS after 24 h and the reporter gene activity
was assayed 48 h after transfection. Cells were washed once with PBS
buﬀer, pH 7.40 (100 ll), and lysed with 50 ll of lysis buﬀer (0.25 M
Tris–HCl, pH 8.0, and 0.5% NP-40). The b-galactosidase activity per
well was estimated by adding 50 ll of 2 substrate solution (1.33 mg/
ml of ONPG, 0.2 M sodium phosphate, pH 7.30, and 2 mM magne-
sium chloride) to the cell lysate in a 96-well plate. Absorption of the
product ortho-nitrophenol at 405 nm was converted to absolute b-
galactosidase units by using a calibration curve constructed with pure
(commercial) b-galactosidase enzyme. The transfection values reported
are the average values from two replicate experiments performed in the
same plate on the same day. Each transfection experiment was per-
formed three times on three diﬀerent days. The day to day variation in
transfection eﬃciency was mostly within 2–3-fold and was dependent
on the cell density and condition of the cells.
2.7. X-gal staining
Cells expressing b-galactosidase were histochemically stained with
the substrate 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-
gal) as described previously [35]. Brieﬂy, forty eight hours after
transfection with lipoplexes in 96-well plates, the cells were washed two
times (2 100 ll) with phosphate-buﬀered saline (PBS, 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4, pH 7.4) and
ﬁxed with 0.5% glutaraldehyde in PBS (225 ll). After 15 min incuba-
tion at room temperature, the cells were washed again with PBS three
times (3 250 ll) and were stained subsequently with 1.0 mg/ml X-gal
in PBS containing 5.0 mM K3[Fe(CN)6], and 5.0 mM K4[Fe(CN)6]
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208 V.V. Kumar, A. Chaudhuri / FEBS Letters 571 (2004) 205–211and 1 mM MgSO4 for 2–4 h at 37 C. Blue colored cells were iden-
tiﬁed by light microscopy (Leica, Germany). A minimum of 100
cells were counted to determine the percentage of cells expressing
b-galactosidase.
2.8. DNA binding assay
The DNA binding ability of the cationic lipids 1 and 2 (Fig. 5A) was
assessed by their gel retardation assay on a 1% agarose gel (pre-stained
with ethidium bromide) across the varying lipid:DNA charge ratios of
0.5:1 to 4:1. pCMV-b-gal (1 lg) was complexed with the varying
amount of cationic lipids in a total volume of 50 ll in HEPES buﬀer
(pH 7.40) and incubated at room temperature for 30 min. 10 ll of 6
loading buﬀer (0.25% Bromophenol blue in 40%, w/v, sucrose in H2O)
was added to it and 20 ll from the resulting 60 ll solution was loaded
on each well. The samples were electrophoresed at 90 V for 2 h and the
DNA bands were visualized in a gel documentation unit.
2.9. DNase I sensitivity assay
Brieﬂy, in a typical assay pCMV-b-gal (1 lg) was complexed with
the varying amount of cationic lipids 1 and 2 (using indicated li-
pid:DNA charge ratios in Fig. 5C) in a total volume of 40 ll in HEPES
buﬀer, pH 7.40, and incubated at room temperature for 30 min on a
rotary shaker. Subsequently, the complexes were treated with 10 ll
DNase I (at a ﬁnal concentration of 1 lg/ml) in the presence of 20 mM
MgCl2 and incubated for 20 min at 37 C. The reactions were then
halted by adding EDTA (to a ﬁnal concentration of 50 mM) and in-
cubated at 60 C for 10 min in a water bath. The aqueous layer was
washed with 50 ll of phenol:chloroform:isoamylalcohol (25:24:1
mixture, v/v) and centrifuged at 10 000 g for 5 min. The aqueous
supernatants were separated, loaded (20 ll) on a 1% agarose gel (pre-
stained with ethidium bromide) and electrophoresed at 90 V for 2 h.0
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 LipofectamineC2.10. Monitoring glutathione-induced DNA release from
DNA–liposome complexes
One microgram of plasmid DNA was dissolved in 10 ll of 10 mM
HEPES buﬀer (pH 7.4). Cationic liposomes with Lipids 1 or 2 were
added to the pDNA solution to obtain ﬁnal lipid:DNA (þ=) charge
ratio of 4:1 (Fig. 5B). After the complexes were incubated for 30 min at
room temperature, 10 ll of 50 mM of glutathione in 10 mM HBS (pH
7.3) was added to the mixture to reach a ﬁnal 10 mM concentration of
glutathione. The mixtures were incubated at 37 C for 20 h. Released
DNA was visualized by 1% agarose gel electrophoresis.
2.11. Cell viability assay
Cytotoxicities of the cationic lipids were assessed using MTT re-
duction assay as described earlier [36]. The cytotoxicity assay was
performed in 96-well plates by maintaining the same ratio of cell to the
amount of cationic lipid as in transfection experiments. Brieﬂy, 3 h
after the addition of lipoplexes, MTT (5 mg/ml PBS) was added to the
cells and incubated for 3–4 h at 37 C in a CO2 incubator. Results are
expressed as percent viability¼ [A550(treated cells))background]/
[A550(untreated cells))background] 100.
2.12. Liposome and lipoplex size measurements
The nano-sizes of the liposomes and lipoplexes in HEPES buﬀer, pH
7.4, were measured by dynamic laser light scattering technique (Zeta-
sizer 3000HAS, Malvern Instruments, UK). The system was calibrated
by using the 199 6 nm NanosphereTM Size Standard (Duke Scientiﬁc
Corp., Palo Alto, CA, USA) and DTS 0050 standard from Malvern.Fig. 2. Transfection eﬃciencies of cationic lipids 1 and 2 and lipofec-
tamine in CHO (A), COS-1 (B) and MCF-7 (C) cells. The b-galactosi-
dase activities in eachwell were converted to an absolute b-galactosidase
milliunits using standard curve obtained with pure (commercial)
b-galactosidase. All the lipids were tested on the same day and the data
shown are the average values of three replicate experiments performed
on the same day (n ¼ 3). Each transfection experiment was performed
three times on three diﬀerent days.3. Results and discussion
Lipid 1 (Fig. 1) was designed and synthesized in our on-going
structure–activity program in the area of liposomal gene de-
livery [25–30] as a non-glycerol based mono-cationic lipid
where the positively charged terminal amine group was sepa-
rated from the hydrophobic aliphatic tails by a reasonably long
spacer arm. Fig. 2A–C summarizes the eﬃcacies of lipids 1 and
2 (used as cationic liposomes prepared in combination with
cholesterol at a mole ratio of 2:1) in transfecting CHO, COS-1
and MCF-7 cells across the increasing lipid:DNA mole ratios0.5:1.0–4.0:1.0 (using pCMV-SPORT-b-gal plasmid as the re-
porter gene). After observing the remarkably high eﬃcacies of
lipid 1 in transfecting CHO, COS-1 and MCF-7 cells (Fig. 2A–
C), the elegant disulﬁde-linker strategy pioneered by Tang and
Fig. 3. Histochemical X-gal staining of transfected CHO cells with lipids 1 and 2 at lipid:DNAmole ratio of 1:1. Cells expressing b-galactosidase were
stained with X-gal as described in the text.
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Fig. 4. Representative percent cell viabilities of cationic lipids 1 and 2
in CHO cells using MTT-based assay. The absorption obtained for
reduced formazan formed in cells untreated with cationic lipids was
taken to be 100. The toxicity assays were performed as described in the
text. The data presented are average values of duplicate experiments
(n ¼ 2). Results were expressed as percent viability¼ [A550(treated
cells)) background]/[A550(untreated cells)) background]· 100.
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enhancing the gene transfer properties of the mono-cationic li-
pid 1.With this view inmind,we designed and synthesized lipid 2
as the disulﬁde-linker analog of lipid 1. Based on the rationale of
the disulﬁde-linker strategy, our expectation was that the in-
tracellular glutathione pool would reduce the disulﬁde bond of
lipid 2 inside the cytoplasm thereby inducing its improved
transfection eﬃcacies via signiﬁcant cytoplasmic release of
plasmidDNA. In stark contrast to such expectations, lipid 2was
found to be essentially incompetent compared to lipid 1 in
transfecting COS-1, CHO and MCF-7 cells (Fig. 2A–C). The
whole cell histochemical X-gal staining of representative CHO
cells (Fig. 3) further conﬁrmed the strikingly unexpected relative
transfection proﬁles of lipids 1 and 2 observed in the reporter
gene assay (Fig. 2A–C).
Towards gaining insights into whether the dramatically un-
expected in vitro DNA transfection proﬁles of lipids 1 and 2
were due to their varying inherent toxicity proﬁles, MTT-based
cell viability assays were performed in representative CHO
cells across the entire range of lipid:DNA mole ratios used in
the actual transfection experiments. Per cent cell viabilities of
both lipids 1 and 2 were found to be remarkably high upto
lipid:DNA charge ratio 4:1 (>80% cell viability, Fig. 4). Thus,
the phenomenally unexpected relative transfection eﬃcacies of
lipids 1 and 2 (Figs. 2 and 3) are unlikely to originate from
varying cell cytotoxicities of the lipids. Next, with a view to
understand whether or not the surprising relative transfection
proﬁles could originate due to varying lipid:DNA binding in-
teractions, we performed the conventional gel retardation as-
says by loading lipoplexes having lipid:DNA charge ratios
across the range 4:1–0.5:1 on a 1% agarose gel. Intensities of
free unassociated DNA bands for lipoplexes 1 were found to
be signiﬁcantly less than those for lipoplexes 2 at lipid:DNA
charge ratios 4:1, 2:1 and 1:1 (Fig. 5A). Such electrophoretic
gel pattern (Fig. 5A) supports the notion that relatively poor
lipid:DNA binding interactions might play an important role
in abolishing the in vitro gene transfer properties of lipid 2.
Although lipid:DNA binding interactions in lipoplex 2 were,
in general, found to be weaker than those for lipoplex 1, such
interactions were not too week for lipoplex 2 at higher li-
pid:DNA charge ratios of 4:1 and 2:1 (Fig. 5A). The gel pat-
terns indicated that the lipid:DNA binding interactions were
approximately similar in lipoplex 2 with 4:1 lipid:DNA charge
ratio and lipoplex 1 with 1:1 lipid:DNA charge ratio (Fig. 5A).In spite of such similar lipid:DNA interactions, what appeared
very surprising to us is that lipid 1 was highly competent at 1:1
lipid:DNA charge ratio in transfecting all three cell lines (with
eﬃcacies better than or comparable to that of LipofectAmine,
most widely used commercially available liposomal transfec-
tion kits) and yet lipid 2 was essentially transfection incom-
petent at 4:1 lipid:DNA charge ratio (Fig. 2). Since lipid 2 was
found to be essentially incompetent in transfecting all three
cells across the entire lipid:DNA charge ratios (Fig. 2), next we
decided to check whether or not the disulﬁde-linker of lipoplex
2 is reducible by glutathione. Towards this end, we performed
a representative gel retardation assay in the presence of 10 mM
glutathione using lipoplexes 1 and 2 with lipid:DNA charge
ratio of 4:1. Consistent with the rationale of the disulﬁde-lin-
ker strategy, signiﬁcant DNA was released from lipoplex 2
when incubated for 20 h in the presence of 10 mM glutathione
and the gel patterns for lipoplex 1 were found to be completely
insensitive to glutathione (Fig. 5B). Thus, the possibility of
ineﬃcient cytoplasmic reduction by the intracellular glutathi-
one pool is unlikely to play any key role behind the severely
compromised transfection properties of lipid 2.
Fig. 5. Electrophoretic gel retardation and DNase I sensitivity assays. (A–C) depict gel patterns observed with pure lipoplexes, lipoplexes in the
presence of 10 mM glutathione and lipoplexes treated with DNase I, respectively. The lipid:DNA charge ratios used in gel retardation assays with
pure lipoplex (A) and in DNase I sensitivity assay (C) are indicated at the top of each lane. A lipid:DNA charge ratio of 4:1 was used in gel re-
tardation assay in the presence of glutathione (B). The details of treatment are as described in the text.
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DNase I sensitivity proﬁles of lipoplexes 1 and 2, DNase I
protection experiments across the entire range of the li-
pid:DNA charge ratios were carried out by incubating the
lipoplexes with DNase I. After the free DNA digestion by
DNase I, the total DNA (both digested and inaccessible DNA)
was separated from the lipid and DNase I (by extracting with
organic solvent) and loaded onto a 1% agarose gel. Fig. 5C
depicts the electrophoretic gel patterns observed for lipids 1
and 2 in DNase I sensitivity assays. Band intensities of any
inaccessible, and therefore undigested, DNA associated with
transfection incompetent lipoplexes prepared from lipid 2 were
practically invisible compared to those associated with the
most transfection eﬃcient lipoplexes made from lipid 1 across
the range of lipid:DNA charge ratios of 4:1 to 0:5:0.1
(Fig. 5C). Such gel patterns in DNase I sensitivity assays in-
dicate that the plasmid DNA associated with lipid 2 is ex-
tremely susceptible to degradation by cellular DNase I than
the DNA complexed to lipid 1. Taken together, the ﬁndings in
the DNase I protection experiments (Fig. 5C) and gel retar-
dation assays (Figs. 5A and B) are consistent with the notion
that transfection incompetency of lipid 2 is likely to originate,
in part, from extreme DNase I sensitivities of the lipoplex 2.
However, the origin of such strikingly contrasting DNase I
sensitivities for lipoplexes 1 and 2 remains elusive at this stage
of investigation.
The nano-sizes of the lipoplexes prepared from lipids 1 and 2
across the varying lipid:DNA charge ratios (4:1–0.5:1) were
measured using dynamic laser light scattering technique and
the sizes of more than 90% of the lipoplex population were
found to vary within 130–240 nm (data not shown). Based onsuch similar lipoplex size range and the same mono-cationic
nature of both lipids 1 and 2, the endocytotic cellular uptake
eﬃciencies for the lipoplexes 1 and 2 are unlikely to be dra-
matically diﬀerent. Interestingly, the cellular uptake of plasmid
DNA complexed with a transfection eﬃcient cholesterol-based
disulﬁde-linker containing cationic lipid has been reported
earlier to be even less than that of lipoplexes prepared from the
corresponding non-disulﬁde transfection-ineﬃcient counter-
part [32]. Thus, correlating cellular uptake eﬃciency and
transfection eﬃcacies are not that straightforward. Flow cy-
tometry experiments involving the use of ﬂuorescently labeled
plasmid DNA need to be carried out in the future to measure
the relative cellular uptake eﬃciencies of lipoplexes 1 and 2.
However, given the extreme DNase I sensitivity of lipid 2, ﬂow
cytometric technique may also fail to provide much useful
insights towards this end. To conclude, results in our DNase I
protection experiments and the electrophoretic gel patterns in
the presence of glutathione indicate that the success of the
disulﬁde-linker strategy may depend more critically on the
DNase I sensitivity of the lipoplexes than on the eﬃcient DNA
release induced by intracellular glutathione pool.
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